



## ONCOLYTIC PEPTIDES *FIRST*

Edwin Klumper  
CEO

November 2018

# DISCLAIMER


THIS PRESENTATION AND ANY OTHER INFORMATION DISCUSSED AT THE PRESENTATION (THE “**PRESENTATION**”) IS BEING PROVIDED TO YOU SOLELY FOR YOUR INFORMATION. THIS PRESENTATION, WHICH HAS BEEN PREPARED AND IS ISSUED BY LYTIX BIOPHARMA AS (“**LYTIX**”), IS PRELIMINARY IN NATURE, BASED ON MANAGEMENT VIEWS AND IS SUBJECT TO UPDATING, REVISION AND AMENDMENT. THIS PRESENTATION MAY NOT BE REPRODUCED IN ANY FORM, FURTHER DISTRIBUTED OR PASSED ON, DIRECTLY OR INDIRECTLY, TO ANY OTHER PERSON, OR PUBLISHED, IN WHOLE OR IN PART, FOR ANY PURPOSE. BY REVIEWING THIS INFORMATION, YOU ARE ACKNOWLEDGING THE CONFIDENTIAL NATURE OF THIS INFORMATION AND ARE AGREEING TO ABIDE BY THE TERMS OF THIS DISCLAIMER.

This Presentation has been prepared solely for informational purposes, and is not intended to, constitute or form part of, and should not be construed as, (i) any offer, solicitation or invitation to subscribe for, sell or issue, underwrite or otherwise acquire any shares, securities or financial instruments of Lytix (the “**Securities**”), nor shall it, or the fact of its communication, form the basis of or be relied upon in connection with or act as any inducement to enter into any contract or commitment whatsoever with respect to any Securities; or (ii) any form of financial opinion, recommendation or investment advice with respect to any Securities. Neither Lytix nor any of its directors, officers, employees, agents or advisers makes any representation or warranty in respect of the accuracy or completeness of the contents of the Presentation or otherwise in relation to the company or its business, and responsibility and liability (whether direct or indirect, express or implied, contractual, tortious, statutory or otherwise) is therefore expressly disclaimed.

This Presentation is strictly confidential. You and your directors, officers, employees, agents and affiliates must hold this Presentation and any oral information provided in connection with this Presentation in strict confidence and may not communicate, reproduce, distribute or disclose it to any other person, or refer to it publicly, in whole or in part, at any time except with our prior written consent. If you are not the intended recipient of this Presentation, please delete and destroy all copies immediately.

This Presentation contains forward-looking statements and assumptions. The words ‘regard’, ‘refer to’, ‘assess’, ‘expect’, ‘anticipate’, ‘plan’ or similar expressions indicate some of these forward-looking statements. Other such statements are identified on the basis of the context. Although Lytix believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurances that they will materialize or prove to be correct. Because these statements are based on assumptions or estimates and are subject to risks and uncertainties, the actual results, financial condition, performance or achievements of Lytix may be materially different from any expected results, financial condition, performance or achievements expressed or implied by such forward-looking statements. There can be no guarantee that any of the research and/or development projects described in this Presentation will succeed or that any new products will be brought to market. Further, there can be no guarantee that Lytix or any future product will achieve any particular level of revenue. In particular, management’s expectations could be affected by, *inter alia*, uncertainties involved in the development of new pharmaceutical products, including unexpected preclinical and clinical trial results, unexpected regulatory actions or delays or government regulation in general, as well as the company’s ability to obtain or maintain patent or other proprietary intellectual property protection.

All statements (including forward looking statements) contained herein are made as of the date of this Presentation. Lytix expressly undertakes no obligation to update or revise this Presentation in case such estimates, projections or forward-looking statements do not materialize or change in the future and disclaims any such obligation to do so. Accordingly, prospective investors are cautioned not to place undue reliance on any of the forward-looking statements herein.




Lytix Biopharma is a private clinical-stage biotech company developing proprietary **oncolytic peptides** as a novel immune therapy to fight cancer

Lead compound **LTX-315 turns cold tumors hot** using the patient's own tumor as source of antigens and generates a **personal immune response**

Local treatment with **LTX-315 targets the first step** in the cancer immunity cycle with a potential **cornerstone position in immunotherapy**


# PROPRIETARY ONCOLYTIC PEPTIDE PLATFORM



IPR protected by multiple patent families until 2037

# IMMUNO-ONCOLOGY MARKET OPPORTUNITY

## MALIGNANT MELANOMA



## CHECKPOINT INHIBITORS


Drivers of the fast growing immuno-oncology market

Limited efficacy even in melanoma, the most immune sensitive tumor type

Effective in **T cell inflamed** or so-called "**hot**" tumors


# LTX-315 TURNS COLD TUMORS HOT

## BEFORE TREATMENT



paired biopsies from a breast cancer patient


## AFTER TREATMENT



**CD8** : immunohistochemistry staining of Tumor Infiltrating Lymphocytes (TILs)



# LTX-315 BREAKS DOWN CANCER CELL MEMBRANES (LYSIS)




- Providing access to the patient's own cancer antigens
- Generating a personal "polyclonal" immune response

LTX-315 enables the immune system to recognize the patient's unique barcode to generate tumor specific killer T cells that attack the cancer at its root cause




# LTX-315 LOCAL TREATMENT LEADS TO SYSTEMIC EFFICACY



Patient with recurrent metastatic leiomyosarcoma after primary surgical resection. Treatment with local intratumoral LTX-315 injections in the buttock muscle lesion.



# LTX-315 *FIRST* TO START THE CANCER IMMUNITY CYCLE



**Immune therapy is all about T-cells:**

- the right T cells
- enough T cells
- potent T cells

An effective immune response starts locally in the tumor with **first having access to antigens** that are patient and tumor specific

# LTX-315 PHASE I STUDY COMPLETED

- 27 evaluable patients
- Safe and tolerable with majority of toxicities grade 1-2 and transient
- 44% stable disease although generally short-lived
- 81% injected tumors turned **cold to hot**
- Systemic **polyclonal T cell responses**
- Systemic responses in distant **non-injected lesions**
  - › Soft-tissue sarcoma in 4 out of 5 patients
  - › Melanoma in 6 out of 8 patients

# LTX-315 DEVELOPMENT TARGETING UNMET MEDICAL NEEDS

## 1 SOFT-TISSUE SARCOMA

- Combination with ATCT
- Open for recruitment
- Poor standard treatment advanced disease
- Orphan disease designation
- Regulatory fast track potential
- Competitive advantage over ATCT alone, Oncolytic Viruses or Vaccines

ATCT: Adoptive T Cell Transfer  
(also known as TIL therapy)

## 2 CPI-resistant MELANOMA

- Combination with Ipilimumab
- Planned for 2019
- In 40% melanoma no durable responses
- Overcome resistance by providing access to new additional antigens generating new tumor specific T cells
- Preclinical synergy LTX-315 / Ipilimumab

# LYTIX BIOPHARMA HIGHLIGHTS

## Proprietary Platform

- First-in-class and only oncolytic peptides in immuno-oncology
- Patent portfolio with protection until 2037

## Market Opportunity

- Potential cornerstone in immunotherapy in multiple tumor types
- Two clinical lead programs in unmet medical needs

## Value triggers


- Multiple triggers with different combination studies in different indications
- Pipeline with 2nd generation LTX-401 in late stage preclinical development

## Business Model

- In-house product development
- Co-development and license agreements

## Management Team

- International pharmaceutical drug development and commercial experience
- Strong international immuno-oncology expert network and collaborations



## ONCOLYTIC PEPTIDES *FIRST*

**Edwin Klumper CEO**

+31630409694

edwin.klumper@lytixbiopharma.com

**Gjest Breistein CFO**

+4795260512

gjest.breistein@lytixbiopharma.com